zurück

Lisocabtagene maraleucel (diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3b (FL3B); ≥ 2 prior therapies)

 

Subject:

  • Active Substance: Lisocabtagene maraleucel
  • Name: Breyanzi®
  • Therapeutic area: Diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B)
  • Pharmaceutical company: Bristol-Myers Squibb GmbH

 

Time table:

  • Start: 01.09.2022
  • Final decision by G-BA: 06.04.2023

 

Final decision:

  • No additional benefit proved